Refractory anemia with ringed sideroblasts associated with thrombocytosis: Comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status

International Journal of Hematology

Volumn 88, Issue 4, 2008, Pages 387-395

  Raya, J M ^a   Arenillas, L ^a   Domingo, A ^a   Bellosillo, B ^a   Gutierrez G ^a   Luno E ^a   Pinan M A ^a   Barbon M ^a   Perez Sirvent M L ^a   Muruzabal M J ^a   Yanez L ^a   Garcia L ^a   Lemes, A ^a   Navarro, J T ^a   Elosegi, A ^a   Cortes M A ^a   Villegas, A ^a   Duran M A ^a   Ardanaz, M ^a   Florensa, L ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

JAK2 mutation; Refractory anemia; Ringed sideroblasts; Thrombocytosis

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; REFRACTORY ANEMIA; RETROSPECTIVE STUDY; SIDEROBLASTIC ANEMIA; THROMBOCYTE COUNT; THROMBOCYTOSIS; AMINO ACID SUBSTITUTION; BLOOD; BONE MARROW CELL; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANEMIA, REFRACTORY; BONE MARROW CELLS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOSIS;

EID: 64249155712     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0169-1     Document Type: Article

References (25)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC press; 2001.
2. Raya JM, Florensa L, Domingo A, Arenillas L, Alonso E, Letamendi G, et al. Refractory anaemia with ringed sideroblasts associated with thrombocytosis: results from a Spanish multicentric study. In: 12th European Haematology Association (EHA) Congress, Vienna, abstract 1137; 2007.
3. RL Levine C Belisle M Wadleigh D Zahrieh S Lee P Chagnon 2006 X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not in ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis Blood 107 4139 41 10.1182/blood-2005-09-3900
4. GR Shaw 2005 Ringed sideroblasts wit thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults Br J Haematol 131 180 4
5. A Tefferi M Elliott 2007 Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F Semin Thromb Hemost 33 313 20 10.1055/s-2007-976165
6. B Bain 2006 Ringed sideroblasts wit thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults Br J Haematol 134 340 10.1111/j.1365-2141.2006.06172.x
7. A Tefferi DG Gilliland 2005 JAK2 in myeloproliferative disorders is not just another kinase Cell Cycle. 4 1053 6
8. A Tefferi A Pardanani 2006 Mutation screening for JAK2V617F: when to order the test and how to interpret the results Leuk Res 30 739 44 10.1016/j.leukres.2006.01.004
9. A Tefferi DG Gilliland 2005 The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis Mayo Clin Proc 80 947 58
10. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology (Am Soc Hematol Educ Program). 2006; 240-5. doi: 10.1182/asheducation-2006.1.240 .
11. JJ Michiels H De Raeve Z Berneman D Van Bockstaele K Hebeda K Lam 2006 The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders Semin Thromb Hemost 32 307 40 10.1055/s-2006-942754
12. JJ Michiels Z Bernema D Van Bockstaele H De Raeve W Schroyens 2007 Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF) Pathol Biol (Paris) 55 92 104 10.1016/j.patbio.2006.06.002
13. DP Steensma GW Dewald TL Lasho HL Powell RF McClure RL Levine 2005 The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Blood 106 1207 9 10.1182/blood-2005-03-1183
14. K Ohyashiki Y Aota D Akahane A Gotoh K Miyazawa Y Kimura 2005 The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients Leukemia 19 2359 60 10.1038/sj.leu.2403989
15. SA Wang RP Hasserjian JM Loew EV Sechman D Jones S Hao 2006 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping mieloproliferative and myelodysplastic features Leukemia 20 1641 4 10.1038/sj.leu.2404316
16. K Nishii R Nanbu VF Lorenzo F Monma K Kato H Ryuu 2007 Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature Leukemia 21 1337 8 10.1038/sj.leu.2404626
17. H Szpurza R Tiu G Murugesan S Aboudola ED His KS Theil 2006 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood 108 2173 81 10.1182/blood-2006-02-005751
18. AF Remacha JF Nomdedéu G Puget C Estivill P Sarda C Canals 2006 Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica 91 719 20
19. M Boissinot R Garand M Hamidou S Hermouet 2006 The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) Blood 108 1781 2 10.1182/blood-2006-03- 008227
20. A Renneville B Quesnel A Charpentier L Terriou A Crinquette JL Laï 2006 High occurrence of JAK2 V617F mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis Leukemia 20 2067 70 10.1038/sj.leu.2404405
21. DP Steensma JS Caudill A Pardanani RF McClure TL Lasho A Tefferi 2006 MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count Haematologica. 91 ECR57
22. MM Ceesay NC Lea W Ingram NB Westwood J Gaken A Mohamedali 2006 The JAK2 V617F mutation is rare in RARS but common in RARS-T Leukemia 20 2060 1 10.1038/sj.leu.2404373
23. 9/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable Blood 109 1334 5 10.1182/blood-2006-05-022491
24. AH Schmitt-Graeff SS Teo M Olschewski F Schaub S Haxelmans A Kirn 2008 JAK2 V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica 93 34 40 10.3324/haematol.11581
25. L Malcovati M Cazzola 2008 Myelodysplastic/myeloproliferative disorders Haematologica 93 4 6 10.3324/haematol.11374